Pfizer Inc. (NYSE:PFE) Shares Sold by Greenleaf Trust

Greenleaf Trust decreased its position in Pfizer Inc. (NYSE:PFE) by 13.4% in the fourth quarter, Holdings Channel reports. The institutional investor owned 266,290 shares of the biopharmaceutical company’s stock after selling 41,316 shares during the period. Greenleaf Trust’s holdings in Pfizer were worth $7,666,000 as of its most recent filing with the SEC.

Several other hedge funds have also modified their holdings of the company. RB Capital Management LLC grew its position in shares of Pfizer by 6.7% in the first quarter. RB Capital Management LLC now owns 5,446 shares of the biopharmaceutical company’s stock valued at $282,000 after purchasing an additional 341 shares during the period. Ironwood Wealth Management LLC. increased its stake in Pfizer by 1.1% during the 1st quarter. Ironwood Wealth Management LLC. now owns 36,081 shares of the biopharmaceutical company’s stock worth $1,868,000 after buying an additional 400 shares in the last quarter. United Bank raised its holdings in shares of Pfizer by 0.6% during the first quarter. United Bank now owns 46,671 shares of the biopharmaceutical company’s stock valued at $2,416,000 after acquiring an additional 290 shares during the last quarter. Ergoteles LLC lifted its position in shares of Pfizer by 136.3% in the first quarter. Ergoteles LLC now owns 36,766 shares of the biopharmaceutical company’s stock valued at $1,903,000 after acquiring an additional 21,209 shares in the last quarter. Finally, Mackenzie Financial Corp increased its position in shares of Pfizer by 6.4% during the first quarter. Mackenzie Financial Corp now owns 1,337,418 shares of the biopharmaceutical company’s stock worth $69,238,000 after purchasing an additional 79,887 shares in the last quarter. 68.36% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several equities research analysts have issued reports on PFE shares. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $45.00 target price on shares of Pfizer in a research note on Monday. Guggenheim started coverage on shares of Pfizer in a research note on Friday, February 23rd. They set a “buy” rating and a $36.00 price objective for the company. Argus lowered shares of Pfizer from a “buy” rating to a “hold” rating in a research note on Friday, March 22nd. Finally, TD Cowen lowered Pfizer from an “outperform” rating to a “market perform” rating and set a $32.00 price target for the company. in a research report on Thursday, January 4th. Twelve equities research analysts have rated the stock with a hold rating and six have given a buy rating to the company’s stock. According to MarketBeat.com, Pfizer currently has an average rating of “Hold” and an average price target of $36.88.

Pfizer Trading Up 2.4 %

Shares of PFE traded up $0.60 during trading on Friday, reaching $25.99. 38,347,117 shares of the company traded hands, compared to its average volume of 42,429,016. The stock has a 50-day simple moving average of $27.14 and a 200-day simple moving average of $28.74. The stock has a market cap of $147.17 billion, a PE ratio of 72.22, a price-to-earnings-growth ratio of 1.15 and a beta of 0.61. Pfizer Inc. has a twelve month low of $25.23 and a twelve month high of $40.37. The company has a quick ratio of 0.69, a current ratio of 0.91 and a debt-to-equity ratio of 0.69.

Pfizer (NYSE:PFE) last posted its quarterly earnings data on Tuesday, January 30th. The biopharmaceutical company reported $0.10 earnings per share for the quarter, topping analysts’ consensus estimates of ($0.19) by $0.29. Pfizer had a net margin of 3.62% and a return on equity of 10.88%. The firm had revenue of $14.25 billion during the quarter, compared to analysts’ expectations of $14.37 billion. During the same quarter last year, the company posted $1.14 EPS. The firm’s quarterly revenue was down 41.3% on a year-over-year basis. On average, analysts anticipate that Pfizer Inc. will post 2.24 earnings per share for the current year.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.